An analysis of 170,628 recipients of autologous and allogeneic HCT reported to CIBMTR between 1968 and 2009 has led researchers to estimate that there will be 242,000 HCT survivors by 2020 and 502,000 HCT survivors by 2030 in the United States. This represents increases of 2.5 times and 5 times, respectively, of the current number of HCT survivors. The researchers conclude that "transplant center providers, hematologists, oncologists, primary care physicians and other specialty providers will need to be familiar with the unique and complex health issues faced by this population."
Study Predicts More Than 500,000 HCT Survivors by 2030 in U.S.
Aug 2013